tiprankstipranks
Trending News
More News >

Gland Pharma Receives SEBI Compliance Certificate for Q1 2025

Story Highlights
Gland Pharma Receives SEBI Compliance Certificate for Q1 2025

Don’t Miss TipRanks’ Half-Year Sale

An update from Gland Pharma Ltd. ( (IN:GLAND) ) is now available.

Gland Pharma Limited has announced the receipt of a Confirmation Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ending March 31, 2025. This certificate, issued by MUFG Intime India Private Limited, confirms the dematerialization status of securities and their listing on stock exchanges, ensuring compliance with regulatory requirements and maintaining transparency for stakeholders.

More about Gland Pharma Ltd.

Gland Pharma Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of complex injectables. The company is known for its extensive portfolio of generic injectables and its emphasis on quality and compliance in its operations.

YTD Price Performance: -21.23%

Average Trading Volume: 11,256

Current Market Cap: 233.1B INR

For detailed information about GLAND stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1